{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:51:38Z","timestamp":1761173498012,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.purol.2013.09.015","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T18:30:28Z","timestamp":1382380228000},"page":"1238-1245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Les m\u00e9dicaments du cancer de vessie"],"prefix":"10.1016","volume":"23","author":[{"given":"L.","family":"Guy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mahammedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bastide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bruyere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Karsenty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-O.","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.purol.2013.09.015_bib0020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/01.ju.0000060782.52358.04","article-title":"Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer: a multicentre study","volume":"170","author":"Jichlinski","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.ju.0000100480.70769.0e","article-title":"Improved detection of urothelial carcinoma in situ with Hexaminolevulinate fluorescence cystoscopy","volume":"171","author":"Schmidbauer","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/01.ju.0000169257.19841.2a","article-title":"Improved detection and treatment of bladder cancer using Hexaminolevulinate imaging: a prospective, phase III multicenter study","volume":"174","author":"Jocham","year":"2005","journal-title":"J Urol"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.purol.2013.09.015_bib0040","doi-asserted-by":"crossref","first-page":"S255","DOI":"10.1016\/S1166-7087(10)70043-9","article-title":"Recommandations en onco-urologie 2010\u00a0: tumeurs uroth\u00e9liales","volume":"20","author":"Pfister","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0045","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.purol.2012.12.002","article-title":"Ciblage diagnostique par Hexvix\u00ae des tumeurs uroth\u00e9liales de vessie\u00a0: r\u00e9sultats apr\u00e8s quatre ans d\u2019\u00e9valuation prospective monocentrique","volume":"23","author":"Ferr\u00e9","year":"2013","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0055","first-page":"1118","article-title":"M\u00e9canismes d\u2019action du BCG\u00a0: vers une approche th\u00e9rapeutique individualis\u00e9e (ATI)\u00a0?","volume":"10","author":"Saint","year":"2000","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus Mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"Bohle","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0075","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin versus Mitomycin C for superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.purol.2013.09.015_bib0080","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin is superior to Mitomycin C in reducing tumour recurrence in high risk superficial bladder cancer: a meta-analysis of randomized trials","volume":"93","author":"Shelley","year":"2004","journal-title":"BJU Int"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.purol.2013.09.015_bib0085","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1086\/314064","article-title":"Efficacy and safety of bacille Calmette-Gu\u00e9rin immunotherappy in superficial bladder cancer","volume":"31","author":"Lamm","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.purol.2013.09.015_bib0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000474529","article-title":"BCG update: intravesical therapy","volume":"31","author":"Martinez-Pineiro","year":"1997","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0095","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Gu\u00e9rin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0100","first-page":"647","article-title":"\u00c9tude de la tol\u00e9rance et de l\u2019efficacit\u00e9 des instillations endov\u00e9sicales de Bacille Calmette-Gu\u00e9rin dans le traitement prophylactique des tumeurs superficielles de vessie, en utilisant un traitement d\u2019entretien","volume":"11","author":"Saint","year":"2001","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0105","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus Calmette-Gu\u00e9rin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-5347(17)48996-8","article-title":"Preliminaryresults of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitionalcellcarcinoma of the urothelium","volume":"133","author":"Sternberg","year":"1985","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0130","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/annonc\/mdj079","article-title":"Systemic chemotherapy in inoperable or metastaticbladder cancer","volume":"17","author":"Bamias","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.purol.2013.09.015_bib0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.ju.0000162039.38023.5f","article-title":"Update on chemotherapy for advanced bladder cancer","volume":"174","author":"Rosenberg","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2013.09.015_bib0140","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1200\/JCO.2006.08.0564","article-title":"Systemic chemotherapy for advanced bladder cancer: update and controversies","volume":"24","author":"Garcia","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2013.09.015_bib0145","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJM199004193221607","article-title":"Biology and management of bladder cancer","volume":"322","author":"Radhavan","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.purol.2013.09.015_bib0150","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2013.09.015_bib0155","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven-year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.purol.2013.09.015_bib0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/sonc.2002.30755","article-title":"Future directions for gemcitabine in the treatment of genitourinary cancer","volume":"29","author":"Vogelzang","year":"2002","journal-title":"Semin Oncol"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.purol.2013.09.015_bib0165","first-page":"31","article-title":"Gemcitabine in bladder cancer","volume":"27","author":"Sternberg","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.purol.2013.09.015_bib0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1586\/14737140.3.1.11","article-title":"Gemcitabine in transitional cell carcinoma of the urothelium","volume":"3","author":"von der Maase","year":"2003","journal-title":"Expert Rev AnticancerTher"},{"key":"10.1016\/j.purol.2013.09.015_bib0175","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/oxfordjournals.annonc.a058775","article-title":"Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase 1\u00a0study","volume":"5","author":"Pollera","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.purol.2013.09.015_bib0180","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2013.09.015_bib0185","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.purol.2013.09.015_bib0190","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670871300701X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670871300701X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:23:26Z","timestamp":1761114206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S116670871300701X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":28,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S116670871300701X"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2013.09.015","relation":{},"ISSN":["1166-7087"],"issn-type":[{"type":"print","value":"1166-7087"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les m\u00e9dicaments du cancer de vessie","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2013.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}